AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Observational Study Evaluate Pathology Practice Use Artificial Intelligence in Patient Suspected Lung and Breast Cancer
Not yet recruiting
- Conditions
- Lung CancerBreast Cancer
- First Posted Date
- 2025-02-14
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 600
- Registration Number
- NCT06827132
REAL-WORLD DURVALUMAB IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Recruiting
- Conditions
- Small Cell Lung Carcinoma
- First Posted Date
- 2025-02-14
- Last Posted Date
- 2025-04-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 90
- Registration Number
- NCT06826677
- Locations
- 🇮🇹
Research Site, Vimercate, Italy
Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease
Phase 2
Recruiting
- Conditions
- APOL1-Mediated Kidney Disease
- First Posted Date
- 2025-02-13
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 96
- Registration Number
- NCT06824987
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004
- First Posted Date
- 2025-02-07
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32
- Registration Number
- NCT06813781
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD2389
- First Posted Date
- 2025-02-06
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT06812780
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
A Safety, Pharmacokinetic, and Pharmacodynamic Study of Once Daily Inhaled AZD8630 in Adults With Asthma
- First Posted Date
- 2025-01-28
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT06795906
- Locations
- 🇩🇪
Research Site, Mainz, Germany
The Anifrolumab PRIM Program
- First Posted Date
- 2025-01-28
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 240
- Registration Number
- NCT06795893
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
Phase 1
Recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Drug: AZD9793 Intravenous (IV) monotherapyDrug: AZD9793 Subcutaneous (SC) monotherapy)
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 304
- Registration Number
- NCT06795022
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
Phase 2
Recruiting
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT06792695
- Locations
- 🇬🇧
Research Site, Wirral, United Kingdom
Study That Will Evaluate the Brazilian Population With COPD.
Recruiting
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease)
- First Posted Date
- 2025-01-17
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 693
- Registration Number
- NCT06780046
- Locations
- 🇧🇷
Centro de Pesquisa Clinica do Instituto Israelita de Ensino (HIAE), Sao Paulo, Brazil
© Copyright 2025. All Rights Reserved by MedPath